Insider Analysis From Nishith Desai Associates: Learning And Unlearning From Section 3(d) Of The Indian Patents Act (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
By Milind Antani and Gowree Gokhale, Nishith Desai Associates, Mumbai, Indi
You may also be interested in...
Roche's Passage To India: Repetitive Patent Hearings, Uncertain Rulings
Patent litigation is always uncertain, but in India pharma companies confront unusual hurdles: separate proceedings when a patent is challenged by numerous opponents; conflicting rulings; a 10-year review backlog; and a law limiting the patenting of new formulations
Roche's Passage To India: Repetitive Patent Hearings, Uncertain Rulings
Patent litigation is always uncertain, but in India pharma companies confront unusual hurdles: separate proceedings when a patent is challenged by numerous opponents; conflicting rulings; a 10-year review backlog; and a law limiting the patenting of new formulations
India's Expert Group Says Denying Patents To Incremental Innovations Will Not Be TRIPS-Compliant; Evergreening To Be Scrupulously Prevented
MUMBAI - Putting to rest wide speculation about applicability of the controversial Section 3 (d) of the Indian Patents Act, which deals with the treatment of incremental innovations, the Mashelkar Committee report - set up to dwell on Indian patent law issues - has recommended that incremental innovations should be encouraged